Hutchmed adr
Web2 dagen geleden · 4月12日丨和黃醫藥漲逾4%，報24.6港元，總市值208億港元。和黃醫藥今天宣佈將於2024年4月14日至4月19日在美國佛羅里達州奧蘭多召開的美國癌症研究 ... Web28 mrt. 2024 · 52-wk low: $7.39. Bid: $12.65. Ask: $14.20. Company Information. HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments.
Hutchmed adr
Did you know?
WebMB5J88 - Alle Stammdaten und Kennzahlen zum Knock-Out & Open-End Knock-Out auf Hutchinson China MediTech, Realtime-Chart mit Basiswertvergleich und Szenariotabellen Web11 apr. 2024 · HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. …
WebHUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer … Web21 feb. 2024 · As a part of this agreement, Hutchmed will receive $400 million as upfront payment and up to $1.13 billion on closing of this agreement including "potential regulatory, development and commercial sales milestone payments, plus royalties on net sales." Shares of Hutchmed soared by more than 8% following this announcement.
Web6 apr. 2024 · HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented … Web1 dag geleden · Price To Free Cash Flow is a widely used stock evaluation measure. Find the latest Price To Free Cash Flow for HUTCHMED (China) Limited Sponsored ADR (HCM)
Web11 mrt. 2024 · HutchMed, the pharmaceutical unit of tycoon Li Ka-shing ’s flagship CK Hutchison Holdings, led declines among four Hong Kong-listed stocks on Friday after being named in a list of foreign...
Web1 dag geleden · HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China table for 4 p.m. closing data. … lcm 16 and 22Web6 apr. 2024 · Complete HUTCHMED (China) Ltd. ADR stock information by Barron's. View real-time HCM stock price and news, along with industry-best analysis. lcm 16 and 60Web15 mrt. 2024 · HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health … lcm 14 and 6WebPara repetir a transferência com os dados atuais, pode usar a pesquisa abaixo com o API. Obter mais informações lcm15v5 monitor windows driverWeb11 apr. 2024 · HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. lcm 15 and 5Web10 apr. 2024 · Earnings Estimate Revisions for HUTCHMED For the fiscal year ending December 2024, this provider of drug research and development services is expected to earn -$0.54 per share, which is a change... lcm 16 and 6Web13 apr. 2024 · 2 Wall Street research analysts have issued 1-year price objectives for HUTCHMED's shares. Their HCM share price forecasts range from GBX 100 to GBX 220. On average, they anticipate the company's stock price to reach GBX 160 in the next year. This suggests that the stock has a possible downside of 30.3%. lcm 16 and 28